New cancer Drug's impact on other meds tested in healthy men
NCT ID NCT06494761
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed phase 1 trial in 16 healthy men examined whether taking multiple doses of the experimental cancer drug zongertinib changes how the body processes three common drugs: midazolam (a sedative), omeprazole (for heartburn), and repaglinide (for diabetes). Participants received zongertinib daily for two weeks, along with single doses of the other drugs at specific times. By measuring drug levels in the blood, researchers aim to identify potential interactions that could affect dosing in future patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- zongertinib
- What this could lead to
- If successful, this study will help doctors understand how zongertinib interacts with other common drugs, guiding safer dosing for future patients.
- What could go wrong
- This is a small, early-stage trial in healthy volunteers, not patients. The results may not predict interactions in people with illnesses or on other medications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Humanpharmakologisches Zentrum Biberach
Biberach, 88397, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test